Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 28, 2026Clinical & Experimental ImmunologyOpen Access

Selinexor potentiates NK cell activation against multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDaniel T. HardingUniversity of SouthamptonLGLara V. GrahamUniversity of SouthamptonLBLaura BartlettUniversity of Southampton

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Harding et al. (2026) studied this question.

synapsesocial.com/papers/6ab9b6017822ec8fc3d915dehttps://doi.org/10.1093/cei/uxag059
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic preclinical study on the synergy between CD73 inhibitors and selinexor for managing multiple myeloma2025
  2. 2Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape2026 · 1 citations
  3. 3CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma2024 · 8 citations
  4. 4XPO1 inhibition by selinexor blocks nucleo-cytoplasmic trafficking of multiple members of the NF-kb family in MPN cell lines and primary myelofibrosis cells2025 · 1 citations
  5. 5Selinexor for myelofibrosis or a drug in search of a disease?2026